In the case of V-raf murine sarcoma viral oncogene homolog B1 (BRAF)-mutant melanomas, highly selective BRAF and mitogen-activated protein kinase (MEK) inhibitors have shown to improve patient survival [7,8,9]. Here, BRAF is linked to melanoma.